Although biologics currently represent 7.6% of WuXi's total revenue, growthin its biologics manufacturing business is
expected to grow"exponentially" in the third and fourth quarters of 2015, Ge Li,chairman and CEO of WuXi PharmaTech said on
Aug. 14, 2015 in a second-quarterearnings call.
WuXi is experiencing strong demand for its biologics manufacturingcapabilities, which is one of the reasons the company is
expanding its capacityin China via construction of a GMP manufacturing suite. Construction on theplant will begin in early
2016 and the facility is scheduled to be online thesame year, said Li. Executives said the commercial facility has to be
online by2016 to address a $70-million backlog of biologics projects the company has inthe pipeline. In total, WuXi has
planned or is planning 15 GMP manufacturingcampaigns during 2014 and 2015.
A growing biologics business
Li said the company has 50 biologics customers; six of these customers areamong the 20 largest pharmaceutical companies in
the world. Revenue in WuXi’sbiologics division was up 120% in the second quarter and “is expected to doublefor the full
year of 2014.” According to executives, WuXi’s
China Lab Services division grew 14.2%, “driven by rapid growth inbiologics, development services, and growth in lab testing
services.”
Cell therapies are gaining steam
The company’s US Lab Services division “delivered solid 9.6% year-over-yeargrowth, driven by strong growth in cell therapy
and material characterizationservices,” said Edward Hu, CFO and CIO of the company. The company has 15 celltherapy
customers, including NewLink Genetics, with whom it is working on celltherapy candidates for the treatment of pancreatic
cancer.
Strong demand for cell therapies led the company to begin construction on anew cell therapy manufacturing facility in
Philadelphia, which will be finishedin mid-2015. The Philadelphia facility will add cGMP manufacture capabilitiesfor
allogeneic and autologous cell-based therapeutics and will feature modulardesign, single-use equipment, and microcarrier
cell-culture technologies.
In 2008, WuXi discontinued its US biologics manufacturing operations fora time and dedicated its already-existing
Philadelphia, PA, facility to thecompany’s biologics testing, cell banking, and cell therapy services.
UPDATE: In a statement on Aug. 14, 2015, a day after the company's earningscall, WuXi PharmaTech announced it would go
private and sell itself to a newlyformed parent company called New WuXi Life Science Limited.
[来源:Biopharminternational]
版权与免责声明:
① 凡本网注明"来源:仪器信息网"的所有作品,版权均属于仪器信息网,未经本网授权不得转载、摘编或利用其它方式使用。已获本网授权的作品,应在授权范围内使用,并注明"来源:仪器信息网"。违者本网将追究相关法律责任。
② 本网凡注明"来源:xxx(非本网)"的作品,均转载自其它媒体,转载目的在于传递更多信息,并不代表本网赞同其观点和对其真实性负责,且不承担此类作品侵权行为的直接责任及连带责任。如其他媒体、网站或个人从本网下载使用,必须保留本网注明的"稿件来源",并自负版权等法律责任。
③ 如涉及作品内容、版权等问题,请在作品发表之日起两周内与本网联系,否则视为默认仪器信息网有权转载。
谢谢您的赞赏,您的鼓励是我前进的动力~
打赏失败了~
评论成功+4积分
评论成功,积分获取达到限制
投票成功~
投票失败了~